Insights5 min read
Import refusals: the revenue number behind the 483
52,089 India-origin US refusals since 2001. 2025 was the all-time record — ~2.6× 2019 — including heavy drug & biologics volume from household names.
Form 483s and Warning Letters are quality language. Import refusals are CFO language: product that never cleared the US border.
The curve is bending up
52,089 India-origin shipments refused at the US border since Oct 2001 (30,945 human foods; 16,339 drugs & biologics).
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026* |
|---|---|---|---|---|---|---|---|---|
| All products | 1,759 | 1,943 | 1,921 | 1,762 | 2,383 | 3,715 | 4,633 | 1,585 |
| Drugs & biologics | 487 | 1,165 | 856 | 770 | 994 | 1,285 | 1,380 | 628 |
2025 set the all-time record at ~2.6× the 2019 level. This is the commercial endpoint the escalation ladder points at.
Who shows up in drug refusals
Top refused drug shippers since 2023 include household names (approximate counts across name variants in the API pull): Sun Pharma (~136), Cipla (~165), Intas (93), Glenmark (56), Emcure (27).
Inspection findings are how quality teams talk. Refusal counts are how finance hears the same risk — product stuck, revenue delayed, reputation public.
How this connects to the floor
Not every refusal traces to a camera-visible GMP failure. Many do not. But the same plants under inspection pressure are the ones whose CFOs already understand the refusal chart. Continuous evidence between audits is one lever on the quality side of that ledger.